<DOC>
	<DOCNO>NCT02335892</DOCNO>
	<brief_summary>Multi centre , prospective , non interventional study 200-240 UK relapse remit multiple sclerosis patient . Patients complete questionnaire baseline , 3 , 6 12 month .</brief_summary>
	<brief_title>PROFILE - Evaluation QoL PRO Outcomes Patients Taking Fingolimod</brief_title>
	<detailed_description>Multi centre , prospective , non interventional study 200-240 UK relapse remit multiple sclerosis patient assess change QoL PRO outcome measure baseline 12 month start fingolimod . Patients complete 4 questionnaire baseline ( prior first fingolimod dose ) , repeat 3 , 6 12 month interval via post .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients prescribe Gilenya within EU licence No previous exposure Gilenya Patient 's HCP consider patient able complete study questionnaire Patient 1855 year age There exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>